ALNYLAM PHARMACEUTICALS, INC.

Alpha Score of 32 reflects weak overall profile with weak momentum, poor value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company pioneering the development of novel therapeutics based on RNA interference, or RNAi. RNAi represents a natural biological process of gene silencing that enables the creation of a new class of medicines by targeting and potently silencing specific messenger RNAs to prevent disease-causing proteins from being produced. This approach addresses significant unmet medical needs in areas where traditional small molecules or antibodies fall short, such as respiratory syncytial virus infection, hypercholesterolemia, liver cancers, and other diseases. Alnylam Pharmaceuticals Inc. leads in translating RNAi into innovative medicines, supported by foundational patents, proprietary technology, and strategic alliances with major pharmaceutical partners. The company maintains a broad pipeline of investigational RNAi therapeutics, focusing on transformative treatments for patients with rare and prevalent genetic diseases. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals Inc. drives advancements at the forefront of gene-based drug discovery.